MarketMelanotan II
Company Profile

Melanotan II

Melanotan II is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH) that stimulates melanogenesis to facilitate tanning. It may also increase sexual arousal.

Synthesis
In the synthesis of melanotan II, an ε-amino group of lysine and an γ-carboxy group of aspartic acid have their orthogonal protection removed before undergoing a carbodiimide mediated lactamization, leading to an intermediate. This intermediate, when attached to N-acetylnorleucine, forms melanotan II. The entire process can be accomplished in 12 steps with an overall yield of 2.6%, and the product is more than 90% pure without preparative chromatography. ==Mechanism of action==
Mechanism of action
Melanotan II acts as a non-selective agonist of the melanocortin receptors MC1, MC3, MC4, and MC5. Melanotan II produces melanogenesis by activation of the MC1 receptor, whereas its clinically documented sexual effects are thought to be related to its ability to activate the MC4 receptor (though the MC3 is thought to also possibly be involved). ==History and research==
History and research
Research in the early 1960s showed that in rats, administration of α-MSH caused sexual arousal, and work on this continued in many labs up through the 1980s, when scientists at the University of Arizona began attempting to develop α-MSH and analogs as potential sunless tanning agents, and synthesized and tested several analogs, including melanotan-I and melanotan II. Early in the research process one of the scientists, who was conducting experiments on himself with an early tool compound, melanotan II, injected himself with twice the dose he intended to and got an eight-hour erection, along with nausea and vomiting. which changed its name to Clinuvel in 2006. Afamelanotide was approved by the FDA in 2019. Competitive Technologies sued Palatin for breach of contract and tried to claim ownership of bremelanotide; the parties settled in 2008 with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying US$800,000. Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma. Reports of melanomas associated with the use of Melanotan II have coincided with heavy sunbathing and sun bed use. A 2019 study showed Melanotan-II having improved sociability deficits in mice exhibiting autistic features. ==Society and culture==
Society and culture
Numerous products are sold online and in gyms and beauty salons as "melanotan" or "melanotan-1", "melanotan-2" or "Barbie drug" in their marketing. Sale of these products for human use is illegal in many jurisdictions. Starting in 2007, health agencies in various countries began issuing warnings against their use. == See also ==
tickerdossier.comtickerdossier.substack.com